Abstract
Cystic fibrosis (CF) is a hereditary disease caused by mutations in the gene encoding the chloride channel “cystic fibrosis transmembrane conductance regulator” (CFTR). The lack of functional CFTR in CF airways leads to impaired ion and fluid homeostasis of the fluid layer which lines the airway surfaces (ASL). The ASL is important for proper ciliary beat and clearance of mucus from the airways. According to the “low volume hypothesis”, CF airway epithelia hyperabsorb sodium via the epithelial sodium channel (ENaC). Although the contribution of ENaC to CF pathogenesis is still under debate, there is convincing data demonstrating that re-hydration of the ASL might improve mucociliary clearance in CF patients. ASL re-hydration might, amongst other things, be achieved by a block of airway transepithelial sodium absorption with inhibitors of ENaC. This mini-review article describes the role of ENaC in ASL fluid homeostasis and rehydration, and summarizes the current state of the art in the discovery and establishment of compounds which inhibit ENaC activity and may represent pharmacological tools for the treatment of CF.
Keywords: Airway surface liquid, amiloride, CFTR, cystic fibrosis, ENaC, inhibitor, sodium transport.
Current Molecular Pharmacology
Title:ENaC Inhibitors and Airway Re-hydration in Cystic Fibrosis: State of the Art
Volume: 6
Author(s): Mike Althaus
Affiliation:
Keywords: Airway surface liquid, amiloride, CFTR, cystic fibrosis, ENaC, inhibitor, sodium transport.
Abstract: Cystic fibrosis (CF) is a hereditary disease caused by mutations in the gene encoding the chloride channel “cystic fibrosis transmembrane conductance regulator” (CFTR). The lack of functional CFTR in CF airways leads to impaired ion and fluid homeostasis of the fluid layer which lines the airway surfaces (ASL). The ASL is important for proper ciliary beat and clearance of mucus from the airways. According to the “low volume hypothesis”, CF airway epithelia hyperabsorb sodium via the epithelial sodium channel (ENaC). Although the contribution of ENaC to CF pathogenesis is still under debate, there is convincing data demonstrating that re-hydration of the ASL might improve mucociliary clearance in CF patients. ASL re-hydration might, amongst other things, be achieved by a block of airway transepithelial sodium absorption with inhibitors of ENaC. This mini-review article describes the role of ENaC in ASL fluid homeostasis and rehydration, and summarizes the current state of the art in the discovery and establishment of compounds which inhibit ENaC activity and may represent pharmacological tools for the treatment of CF.
Export Options
About this article
Cite this article as:
Althaus Mike, ENaC Inhibitors and Airway Re-hydration in Cystic Fibrosis: State of the Art, Current Molecular Pharmacology 2013; 6 (1) . https://dx.doi.org/10.2174/18744672112059990025
DOI https://dx.doi.org/10.2174/18744672112059990025 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System
Current Medicinal Chemistry Coated with Nanomaterials Intraocular Lenses, Ophthalmic and Human Body Implantable Devices with High Catalytic Antioxidant Activities: A New Nanotechnology Strategy of Peroxidase Cellular Enzyme Mimics Increasing the Biocompatibility and Therapeutic Deployment of the Medical Prosthetic Device
Recent Patents on Drug Delivery & Formulation Development and Evaluation of a Tactile Cognitive Function Test Device for Alzheimer’s Disease Early Detection
Neuroscience and Biomedical Engineering (Discontinued) Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy Joint Occurrence of Pain and Sleep Disturbances in People with Dementia. A Systematic Review
Current Alzheimer Research C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside
Current Neuropharmacology Genetic Markers in Biological Fluids for Aging-Related Major Neurocognitive Disorder
Current Alzheimer Research Molecular Dynamics and Regulation of Butyrylcholinesterase Cholinergic Activity by RNA Binding Proteins
CNS & Neurological Disorders - Drug Targets The Development and Progression of Atherosclerosis: Evidence supporting a Role for Endoplasmic Reticulum (ER) Stress Signaling
Cardiovascular & Hematological Disorders-Drug Targets DNA Minor Groove Binders: an Overview on Molecular Modeling and QSAR Approaches
Current Medicinal Chemistry Nanorobotic Strategy for Nondestructive Mechanical Characterization of Carbon Nanotubes
Micro and Nanosystems A2B Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors
Current Cancer Drug Targets Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Current Molecular Pharmacology The GABAA-BZR Complex as Target for the Development of Anxiolytic Drugs
Current Topics in Medicinal Chemistry Natural Products as Sources of New Lead Compounds for the Treatment of Alzheimer’s Disease
Current Topics in Medicinal Chemistry The Interaction of Dietary Fibres with the Colon
Current Nutrition & Food Science The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Polyunsaturated Fatty Acids in Human Milk and Neurological Development in Breastfed Infants
Current Pediatric Reviews Pathogens and Chronic or Long-Term Neurologic Disorders
Cardiovascular & Hematological Disorders-Drug Targets